openPR Logo
Press release

Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

05-13-2024 11:38 PM CET | Health & Medicine

Press release from: ABNewswire

Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet

DelveInsight's, "Small Lymphocytic Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Small lymphocytic lymphoma Pipeline Report

* DelveInsight's Small lymphocytic lymphoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Small lymphocytic lymphoma treatment.
* The leading Small lymphocytic lymphoma Companies working in the market include Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
* Promising Small lymphocytic lymphoma Therapies in the various stages of development include ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.
* May 2024:- Juno Therapeutics, a Subsidiary of Celgene- An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004). This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose.
* May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010).
* May 2024:- Inhye Ahn- A Phase 2 Study of Fixed Duration Therapy With Pirtobrutinib and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (POP). This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

Request a sample and discover the recent advances in Small lymphocytic lymphoma @ Small lymphocytic lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Small lymphocytic lymphoma Overview

SLL is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood.

Small lymphocytic lymphoma treatment may involve the use of low or high intensity combination chemotherapy, more recently with a targeted therapy such as a monoclonal antibody. This is commonly known as chemo immunotherapy. The combination of drugs will depend on age, stage of disease and risk factors. Small lymphocytic lymphoma that accumulates in the bone marrow and the spleen can deplete the amount of healthy blood cells in the circulating blood (blood that flows throughout the body).

Small lymphocytic lymphoma Emerging Drugs Profile

* TQ-B3525: Chia Tai Tianqing Pharmaceutical Group

TQ-B3525 is a novel and selective oral PI3K / inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K and PI3K in pre-clinical research. TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients.Currently,the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

* LOXO-305: Loxo Oncology

Pirtobrutinib (LOXO-305), is an investigational, oral, highly-selective non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, and marginal zone lymphoma.

* IOV 2001: Iovance Biotherapeutics

IOV 2001 is an adoptive cell therapy consist of autologous peripheral blood lymphocytes (PBL) being developed by Iovance Biotherapeutics. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of SLL.

Learn more about Small lymphocytic lymphoma in clinical trials @ Small lymphocytic lymphoma Drugs [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Small lymphocytic lymphoma Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.

DelveInsight's Small lymphocytic lymphoma pipeline report covers around 80+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Small lymphocytic lymphoma in development @ Small lymphocytic lymphoma Clinical Trials [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Small lymphocytic lymphoma Companies

Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.

Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Small lymphocytic lymphoma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

To know more about Small lymphocytic lymphoma, visit @ Small lymphocytic lymphoma Segmentation [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Small lymphocytic lymphoma Pipeline Report

* Coverage- Global
* Small lymphocytic lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Small lymphocytic lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Small lymphocytic lymphoma Companies- Loxo Oncology, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, and TG Therapeutics represent a diverse array of pharmaceutical companies, each contributing significantly to the advancements in healthcare. Chia Tai Tianqing Pharmaceutical Group, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, and others.
* Small Lymphocytic Lymphoma Therapies- ofatumumab, Ibrutinib, Obinutuzumab, Chlorambucil, Arzerra, FC infusion, and others.

For further information on the Small lymphocytic lymphoma Pipeline Therapeutics, reach out @ Small lymphocytic lymphoma Products Development [https://www.delveinsight.com/sample-request/small-lymphocytic-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Small Lymphocytic Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Small Lymphocytic Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Last Stage Products (Phase III)
* LOXO-305: Loxo Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Small Lymphocytic Lymphoma Key Companies
* Small Lymphocytic Lymphoma Key Products
* Small Lymphocytic Lymphoma - Unmet Needs
* Small Lymphocytic Lymphoma - Market Drivers and Barriers
* Small Lymphocytic Lymphoma - Future Perspectives and Conclusion
* Small Lymphocytic Lymphoma Analyst Views
* Small Lymphocytic Lymphoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=small-lymphocytic-lymphoma-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here

News-ID: 3494828 • Views:

More Releases from ABNewswire

Argentina Colocation Market Surges Toward USD 156 Million by 2030, Buenos Aires Strengthens Its Hub with 19 Sites | Arizton
Argentina Colocation Market Surges Toward USD 156 Million by 2030, Buenos Aires …
Get Insights on 24 Colocation Data Center Facilities across Argentina According to Arizton research, the Argentina data center colocation market [https://www.arizton.com/market-reports/argentina-data-center-colocation-market] size was valued at USD 76 million in 2024 and is expected to reach USD 156 million by 2030, growing at a CAGR of 12.73% during the forecast period Explore the Full Market Insights: [https://www.arizton.com/market-reports/argentina-data-center-colocation-market] Report Summary: MARKET SIZE - COLOCATION REVENUE: USD 156 Million (2030) CAGR - COLOCATION REVENUE: 12.73% (2024-2030) MARKET SIZE -
Global Forklift Attachments Market to Reach USD 5.83 Billion by 2030 | Arizton
Global Forklift Attachments Market to Reach USD 5.83 Billion by 2030 | Arizton
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030. According to Arizton research, the global forklift attachments market [https://www.arizton.com/market-reports/forklift-attachments-market] was valued at USD 3.98 billion in 2024 and is projected to reach USD 5.83 billion by 2030, growing at a CAGR of 6.58% during the forecast year. Explore the Full Market Insights: [https://www.arizton.com/market-reports/forklift-attachments-market] Report Summary: Market Size (2030): USD 5.83 Billion Market Size (2024): USD 3.98 Billion CAGR (2024-2030): 6.58% Historic
Fox Moving & Storage Establishes Industry Standards for Moving Companies Background Screening in Tennessee
Fox Moving & Storage Establishes Industry Standards for Moving Companies Backgro …
Fox Moving & Storage introduces comprehensive background screening that exceeds industry standards, resulting in a 40% reduction in incidents and inspiring Tennessee relocators to adopt enhanced verification protocols. Fox Moving & Storage has implemented a comprehensive background screening protocol that is reshaping safety standards across Tennessee's relocation industry. The Knoxville-based company's rigorous screening process has garnered attention from industry leaders and regulatory bodies, establishing new benchmarks for employee verification procedures that
Movers in Nashville, TN See Record Demand as City Ranks Among America's Fastest-Growing Markets
Movers in Nashville, TN See Record Demand as City Ranks Among America's Fastest- …
Nashville's rapid population growth has increased demand for professional relocation services, prompting Fox Moving & Storage of Nashville to adapt its operations to serve both residential and commercial clients across Tennessee's expanding capital region. Nashville's unprecedented population growth has created a ripple effect across multiple industries, with the relocation sector experiencing particularly notable increases in service requests. The Tennessee capital's designation as one of America's fastest-growing cities has led to heightened

All 5 Releases


More Releases for Small

Succeeding Small Launches Small Business Give-Back Giveaway in Celebration of Sm …
Succeeding Small Launches Small Business Give-Back Giveaway in Celebration of Small Business Month Honoring Local Colorado Springs Businesses That Make a Difference in Their Community COLORADO SPRINGS, CO - Succeeding Small, a go-to guide for small business success in small business marketing, is celebrating Small Business Month with the launch of its Small Business Give-Back Giveaway - a contest aimed at honoring the small, service-based businesses that make a meaningful difference in
Small Molecules, Big Impact: The Rise of the Small Molecule Immunomodulators Mar …
Small Molecule Immunomodulators Market worth $270.8 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Small Molecule Immunomodulators Market - (By Product (Disposable, Reusable), By Application (Colorectal, Thoracic, Orthopedic, Ophthalmology, Neurosurgery, Cardiac Surgery, Gynecology, Others), By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to
Powering Small: Small Gas Engines Market Advances (2023-2032)
"According to the research report, the global small gas engines market was valued at USD 2.75 billion in 2022 and is expected to reach USD 4.23 billion by 2032, to grow at a CAGR of 4.4% during the forecast period." Polaris Market Research has recently published the latest update on Small Gas Engines Market: By Size, Latest Trends, Share, Huge Growth, Segments, Analysis and Forecast, 2030 that offers detailed market analysis,
Small Batch Freeze Dryer Market: Increasing Demand for Small-scale Freeze Drying …
Global Small Batch Freeze Dryer Market Overview: The Small Batch Freeze Dryer market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others. In recent years, the Small Batch Freeze Dryer market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and
Global Small Gas Engines Market, Global Small Gas Engines Industry, Covid-19 Imp …
The Small Gas Engines market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The Global Small Gas Engines Market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Small Gas Engines market. The report focuses on well-known providers
Small Appliances Market: Strategic Assessment of Emerging Technologies in Small …
Small appliances market is forecasted to grow substantially in all market segments through 2016 owing to the rise in living standards and need for more comfort. Small appliance industry consists of home appliances that are movable or partially movable and can be used on tables, counters, or other platforms. The growth of small appliances market is expected to be driven by product innovation, upgradation of existing products, and value-added features